NY Symposium Tackles Emerging Agents, Pressing Questions in Lung Cancer
Published Online: Friday, November 8, 2013
Mark G. Kris, MD
Mark G. Kris, MD, one of the symposium’s program directors, said the conference will cover next-generation approaches and drugs for treating patients with advanced non-small cell lung cancer (NSCLC), including acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and new treatment options for patients with tumors that test positive for the ALK gene translocation. Revised strategies for treating small cell lung cancers, an update on squamous cell lung cancers, and the potential of immune therapy approaches also will be discussed.
Román Pérez-Soler, MD
Román Pérez-Soler, MD, who also is a program director, said the meeting helps fill a need for oncology specialists to keep abreast of rapid advancements in the field. Pérez-Soler is chairman and chief of the Department of Medical Oncology at Montefiore Medical Center and an associate director of Clinical Research at Albert Einstein Cancer Center in Bronx, New York.
“The amount of data being generated on a monthly basis is quite amazing,” said Pérez-Soler. “There is a need to update people almost constantly. It’s a very useful program for people who want to catch up on what’s going on in lung cancer treatment.”
The symposium will feature these presentations:
- Overcoming Resistance to EGFR TKIs
- ALK Inhibitors: State of the Art
- Molecular Targeted Agents for Stage III NSCLC
- New Horizons for Small Cell Lung Cancers
- New Treatments for Squamous Cell Lung Cancer
- Current Approaches to Supportive Care
- Adjuvant Therapy
- How I Approach Maintenance Therapy
- PD-1/PD-L1 Inhibition: What Does the Future Hold?
Faculty members scheduled to make presentations include Alice T. Shaw, MD, of Massachusetts General Hospital and Harvard Medical School; Bryan J. Schneider, MD, of New York Presbyterian-Weill Cornell Medical Center; and Charles M. Rudin, MD, PhD, and Gregory J. Riely, MD, PhD, of Memorial Sloan-Kettering Cancer Center.
For further information, visit www.gotoper.com.
Online CME Activities
Most Popular Right Now